Samsung Bioepis and Organon (OGN) announced that the FDA has designated the Hadlima high- and low-concentration autoinjectors and high-concentration prefilled syringe as interchangeable biosimilars to Humira. These interchangeability designations follow the interchangeability designation received for the Hadlima low-concentration prefilled syringe and single-dose vial in June 2024.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN: